Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamikibart (RO7200220) in Diabetic and Uveitic Macular Edema
NCT06771271Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of vamikibart in diabetic macular edema (DME) and uveitic macular edema (UME) (4 arms), sponsored by Roche. Primary endpoint: Number of Participants With Adverse Events (AEs) up to 36 weeks. Started Jul 2019; status: completed.
02
Drugs
vamikibart
03
Conditions
diabetic macular edema (DME)uveitic macular edema (UME)
Beyond the preview
Go deeper on NCT06771271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771271.